Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, talks about how biosimilars have been able to help patients avoid financial toxicity related to oncology care costs.
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, talks about how biosimilars have been able to help patients avoid financial toxicity related to oncology care costs.
Transcript:
What kind of impact have biosimilars made on easing the financial toxicity of cancer treatment, based on your observations and research with the Community Oncology Alliance (COA)?
Biosimilars have had a huge impact within our practice and amongst the COA practices, as shown in our recent biosimilar data project for COA, which supported our working hypothesis that utilization of biosimilars increased access to care and lowered costs to the practices and patients. So, by making the supportive care and therapeutic agents more affordable, we saw a notable increase in access to care, which is patient usage. And in our practice, we saw an average of about a $200 cost savings per treatment for patients when we were able to utilize biosimilars in their treatment plan.
We also saw about a 25% increase in patient access when being able to utilize biosimilars. And we saw this mirrored in our COA data, in which we reviewed about 2.4 million administrations of both innovator as well as biosimilar products, as well as the therapeutic and the supportive care space. So, we saw throughout the whole COA membership, when we looked at that data, it pretty much mirrored what we saw at a practice level, that there was a an increase in access to care and the products, therefore, became more affordable to the practice as well as the patient.
And when you're talking about patient impact and the biosimilar impact on patients, I like to explain it like financing a car. So, the patient's deductible is x and it's always going to be that x, that fixed amount. But when we're considering all of the other patient financial variables, such as food, utilities, and mortgage, utilization of biosimilars can play a large role in whether the patient is satisfying their deductible in a very small 2-month window or being able to spread that out over maybe 6 months or a little bit longer. So, we're spreading out those costs, and thereby, factoring in a decreased financial toxicity or stress to the patient.
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More